David White's questions to GALECTIN THERAPEUTICS (GALT) leadership • Q4 2015
Question
David White asked for the reasoning behind the removal of Jim Czirr as Chairman and whether CEO Peter Traber had orchestrated the change and assumed his business duties.
Answer
Peter Traber (President, CEO & CMO) clarified that he did not orchestrate the change, stating it was a decision made by the Board of Directors. He explained the board felt it was appropriate to transition leadership to Dr. Marc Rubin, the former Lead Director, to align with the company's shift toward advanced clinical development. Traber affirmed that Jim Czirr remains an important and active member of the board.